股本结构
单位：万股
| 公告日期 | 2024-04-26 | 2024-03-21 | 2024-03-21 | 2023-11-07 | 2023-11-07 | 2023-08-11 |
|---|---|---|---|---|---|---|
| 证券总股本 | 5887.64 | 5813.34 | 4475.49 | 4432.30 | 4429.41 | 3952.68 |
| 普通股本 | 5887.64 | 5813.34 | 4475.49 | 4432.30 | 4429.41 | 3952.68 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-04-18 | 2024-03-20 | 2023-12-31 | 2023-11-06 | 2023-09-30 | 2023-08-10 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-26 | 5887.64 | 未披露 | 定期报告 | 2024-04-18 |
| 2024-03-21 | 5813.34 | 未披露 | 定期报告 | 2024-03-20 |
| 2024-03-21 | 4475.49 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Issuance of common stock to Pfizer Inc.
Shares issued pursuant to at-the-market (“ATM”) program, net of commission
Issuance of shares upon acquisition of Apexigen, Inc. (“Apexigen”)
Stock options exercised
Issuance of restricted common stock, net of tax withholdings
Issuance of common stock under employee stock purchase plan (“ESPP”)
|
2023-12-31 |
| 2023-11-07 | 4432.30 | 未披露 | 定期报告 | 2023-11-06 |
| 2023-11-07 | 4429.41 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Acquisition of Apexigen, Inc.
Vesting of restricted common stock, net of tax withholdings
Issuance of common stock under employee stock purchase plan ("ESPP")
Stock options exercised
|
2023-09-30 |
| 2023-08-11 | 3952.68 | 未披露 | 定期报告 | 2023-08-10 |
| 2023-08-11 | 3937.69 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Stock options exercised
Vesting of restricted common stock
Shares issued pursuant to at-the-market ("ATM") program, net of commission
|
2023-06-30 |
| 2023-06-30 | 3941.43 | 未披露 | 定期报告 | 2023-06-28 |
| 2023-06-29 | 3939.82 | 未披露 | 定期报告 | 2023-06-15 |
| 2023-05-11 | 3824.53 | 未披露 | 定期报告 | 2023-05-10 |
| 2023-04-28 | 3798.42 | 未披露 | 定期报告 | 2023-04-20 |
| 2023-05-11 | 3691.84 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock to Pfizer Inc.
Vesting of restricted common stock
|
2023-03-31 |
| 2023-03-22 | 3698.06 | 未披露 | 定期报告 | 2023-03-21 |
| 2023-03-22 | 3495.87 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock to Pfizer Inc. (Refer to Note 3)
Vesting of restricted common stock
Stock options exercised
|
2022-12-31 |
| 2022-11-01 | 3509.73 | 未披露 | 定期报告 | 2022-11-01 |
| 2022-11-01 | 3258.81 | 未披露 |
更多>>
From July 1, 2022 to September 30, 2022
Stock options exercised
Vesting of restricted common stock
|
2022-09-30 |
| 2022-08-15 | 3283.46 | 未披露 | 定期报告 | 2022-08-15 |
| 2022-08-15 | 3248.39 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Stock options exercised
Vesting of restricted common stock
|
2022-06-30 |
| 2022-05-13 | 3281.71 | 未披露 | 定期报告 | 2022-05-13 |
| 2022-04-28 | 3281.20 | 未披露 | 定期报告 | 2022-04-20 |
| 2022-05-13 | 3237.49 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
Vesting of restricted common stock
Stock-based compensation
|
2022-03-31 |
| 2022-03-29 | 3284.17 | 未披露 | 定期报告 | 2022-03-29 |
| 2022-03-29 | 3222.29 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of Series B convertible preferred stock to Pfizer, Inc.
Issuance of Series B convertible preferred stock, net of issuance costs of $419
Issuance of shares of common stock through initial public offering, net of underwriting commission and issuance costs of $15,704
Conversion of Series A and Series B convertible preferred stock into shares of common stock
Stock options exercised
Vesting of restricted common stock
|
2021-12-31 |
| 2021-11-15 | 3276.39 | 未披露 | 定期报告 | 2021-11-12 |
| 2021-10-08 | 3273.41 | 未披露 |
更多>>
1.Common stock offered by company 10,500,000 shares
2.The number of shares of common stock that will be outstanding after this offering is based on 22,234,101 shares of common stock outstanding as of June 30, 2021
|
2021-10-08 |
From December 31,2022 to December 31,2023
Issuance of common stock to Pfizer Inc.
Shares issued pursuant to at-the-market (“ATM”) program, net of commission
Issuance of shares upon acquisition of Apexigen, Inc. (“Apexigen”)
Stock options exercised
Issuance of restricted common stock, net of tax withholdings
Issuance of common stock under employee stock purchase plan (“ESPP”)
From June 30, 2023 to September 30, 2023
Acquisition of Apexigen, Inc.
Vesting of restricted common stock, net of tax withholdings
Issuance of common stock under employee stock purchase plan ("ESPP")
Stock options exercised
From March 31, 2023 to June 30, 2023
Stock options exercised
Vesting of restricted common stock
Shares issued pursuant to at-the-market ("ATM") program, net of commission
From December 31, 2022 to March 31, 2023
Issuance of common stock to Pfizer Inc.
Vesting of restricted common stock
From December 31, 2021 to December 31, 2022
Issuance of common stock to Pfizer Inc. (Refer to Note 3)
Vesting of restricted common stock
Stock options exercised
From July 1, 2022 to September 30, 2022
Stock options exercised
Vesting of restricted common stock
From March 31, 2022 to June 30, 2022
Stock options exercised
Vesting of restricted common stock
From January 1, 2022 to March 31, 2022
Vesting of restricted common stock
Stock-based compensation
From December 31, 2020 to December 31, 2021
Issuance of Series B convertible preferred stock to Pfizer, Inc.
Issuance of Series B convertible preferred stock, net of issuance costs of $419
Issuance of shares of common stock through initial public offering, net of underwriting commission and issuance costs of $15,704
Conversion of Series A and Series B convertible preferred stock into shares of common stock
Stock options exercised
Vesting of restricted common stock
1.Common stock offered by company 10,500,000 shares
2.The number of shares of common stock that will be outstanding after this offering is based on 22,234,101 shares of common stock outstanding as of June 30, 2021